S&P 500   4,080.11 (+3.09%)
DOW   34,589.77 (+2.18%)
QQQ   293.36 (+4.56%)
AAPL   148.03 (+4.86%)
MSFT   255.14 (+6.16%)
META   118.10 (+7.89%)
GOOGL   100.99 (+6.09%)
AMZN   96.54 (+4.46%)
TSLA   194.70 (+7.67%)
NVDA   169.23 (+8.24%)
NIO   12.78 (+21.71%)
BABA   87.56 (+9.64%)
AMD   77.63 (+5.78%)
T   19.28 (+1.42%)
MU   57.65 (+4.59%)
CGC   3.62 (+5.85%)
F   13.90 (+1.09%)
GE   85.97 (+0.36%)
DIS   97.87 (+3.36%)
AMC   7.23 (-2.69%)
PYPL   78.41 (+0.99%)
PFE   50.13 (+1.29%)
NFLX   305.53 (+8.75%)
S&P 500   4,080.11 (+3.09%)
DOW   34,589.77 (+2.18%)
QQQ   293.36 (+4.56%)
AAPL   148.03 (+4.86%)
MSFT   255.14 (+6.16%)
META   118.10 (+7.89%)
GOOGL   100.99 (+6.09%)
AMZN   96.54 (+4.46%)
TSLA   194.70 (+7.67%)
NVDA   169.23 (+8.24%)
NIO   12.78 (+21.71%)
BABA   87.56 (+9.64%)
AMD   77.63 (+5.78%)
T   19.28 (+1.42%)
MU   57.65 (+4.59%)
CGC   3.62 (+5.85%)
F   13.90 (+1.09%)
GE   85.97 (+0.36%)
DIS   97.87 (+3.36%)
AMC   7.23 (-2.69%)
PYPL   78.41 (+0.99%)
PFE   50.13 (+1.29%)
NFLX   305.53 (+8.75%)
S&P 500   4,080.11 (+3.09%)
DOW   34,589.77 (+2.18%)
QQQ   293.36 (+4.56%)
AAPL   148.03 (+4.86%)
MSFT   255.14 (+6.16%)
META   118.10 (+7.89%)
GOOGL   100.99 (+6.09%)
AMZN   96.54 (+4.46%)
TSLA   194.70 (+7.67%)
NVDA   169.23 (+8.24%)
NIO   12.78 (+21.71%)
BABA   87.56 (+9.64%)
AMD   77.63 (+5.78%)
T   19.28 (+1.42%)
MU   57.65 (+4.59%)
CGC   3.62 (+5.85%)
F   13.90 (+1.09%)
GE   85.97 (+0.36%)
DIS   97.87 (+3.36%)
AMC   7.23 (-2.69%)
PYPL   78.41 (+0.99%)
PFE   50.13 (+1.29%)
NFLX   305.53 (+8.75%)
S&P 500   4,080.11 (+3.09%)
DOW   34,589.77 (+2.18%)
QQQ   293.36 (+4.56%)
AAPL   148.03 (+4.86%)
MSFT   255.14 (+6.16%)
META   118.10 (+7.89%)
GOOGL   100.99 (+6.09%)
AMZN   96.54 (+4.46%)
TSLA   194.70 (+7.67%)
NVDA   169.23 (+8.24%)
NIO   12.78 (+21.71%)
BABA   87.56 (+9.64%)
AMD   77.63 (+5.78%)
T   19.28 (+1.42%)
MU   57.65 (+4.59%)
CGC   3.62 (+5.85%)
F   13.90 (+1.09%)
GE   85.97 (+0.36%)
DIS   97.87 (+3.36%)
AMC   7.23 (-2.69%)
PYPL   78.41 (+0.99%)
PFE   50.13 (+1.29%)
NFLX   305.53 (+8.75%)

Mersana Therapeutics - MRSN Stock Forecast, Price & News

$6.66
+0.04 (+0.60%)
(As of 11/30/2022 05:19 PM ET)
Add
Compare
Today's Range
$6.51
$6.85
50-Day Range
$6.13
$7.86
52-Week Range
$2.68
$8.34
Volume
746,911 shs
Average Volume
1.45 million shs
Market Capitalization
$664.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.25

Mersana Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
144.0% Upside
$16.25 Price Target
Short Interest
Healthy
4.74% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.69
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.26) to ($1.94) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.42 out of 5 stars

Medical Sector

248th out of 1,043 stocks

Pharmaceutical Preparations Industry

98th out of 510 stocks

MRSN stock logo

About Mersana Therapeutics (NASDAQ:MRSN) Stock

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing antibody drug conjugates that offer clinical benefit for cancer patients with significant unmet need. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

Receive MRSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mersana Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRSN Stock News Headlines

Recap: Mersana Therapeutics Q3 Earnings
SVB Securities Keeps Their Buy Rating on Mersana Therapeutics (MRSN)
Mersana Therapeutics, Inc. (NASDAQ: MRSN)
Mersana Jumps on Launch of ONCOLOGY FACETS
Mersana Therapeutics Rings the Closing Bell
See More Headlines
Receive MRSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mersana Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRSN Company Calendar

Last Earnings
11/07/2022
Today
11/30/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/27/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MRSN
Fax
N/A
Employees
169
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.25
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+144.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-170,060,000.00
Net Margins
-1,749.59%
Pretax Margin
-1,749.59%

Debt

Sales & Book Value

Annual Sales
$40,000.00
Price / Sales
16,612.37
Book Value
$0.90 per share

Miscellaneous

Free Float
95,384,000
Market Cap
$664.49 million
Optionable
Not Optionable
Beta
1.74

Key Executives

  • Anna ProtopapasAnna Protopapas
    President, Chief Executive Officer & Director
  • Brian DeSchuytner
    Chief Financial Officer & Senior Vice President
  • Timothy B. LowingerTimothy B. Lowinger
    Chief Science & Technology Officer
  • Arvin YangArvin Yang
    Chief Medical Officer & Senior Vice President
  • Alejandra Veronica Carvajal
    Secretary, Chief Legal Officer & Senior VP













MRSN Stock - Frequently Asked Questions

Should I buy or sell Mersana Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MRSN shares.
View MRSN analyst ratings
or view top-rated stocks.

What is Mersana Therapeutics' stock price forecast for 2023?

4 equities research analysts have issued 12-month price targets for Mersana Therapeutics' stock. Their MRSN share price forecasts range from $12.00 to $20.00. On average, they anticipate the company's share price to reach $16.25 in the next year. This suggests a possible upside of 144.0% from the stock's current price.
View analysts price targets for MRSN
or view top-rated stocks among Wall Street analysts.

How have MRSN shares performed in 2022?

Mersana Therapeutics' stock was trading at $6.22 at the start of the year. Since then, MRSN stock has increased by 7.1% and is now trading at $6.66.
View the best growth stocks for 2022 here
.

When is Mersana Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our MRSN earnings forecast
.

How were Mersana Therapeutics' earnings last quarter?

Mersana Therapeutics, Inc. (NASDAQ:MRSN) posted its earnings results on Monday, November, 7th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.03) by $0.58. The business earned $5.57 million during the quarter, compared to analysts' expectations of $38.57 million. Mersana Therapeutics had a negative trailing twelve-month return on equity of 171.23% and a negative net margin of 1,749.59%.

What is Anna Protopapas' approval rating as Mersana Therapeutics' CEO?

3 employees have rated Mersana Therapeutics Chief Executive Officer Anna Protopapas on Glassdoor.com. Anna Protopapas has an approval rating of 100% among the company's employees. This puts Anna Protopapas in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Mersana Therapeutics own?
When did Mersana Therapeutics IPO?

(MRSN) raised $75 million in an initial public offering on Wednesday, June 28th 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Mersana Therapeutics' stock symbol?

Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."

Who are Mersana Therapeutics' major shareholders?

Mersana Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (7.10%), Vanguard Group Inc. (4.39%), Bellevue Group AG (4.09%), State Street Corp (4.07%), Nuveen Asset Management LLC (1.27%) and Two Sigma Advisers LP (1.12%). Insiders that own company stock include Alejandra Carvajal, Andrew A F Hack, Anna Protopapas, Arvin Yang, Ashish Mandelia, Eva M Jack, Lawrence M Alleva, Lawrence M Alleva, Scott D Sandell, Timothy B Lowinger and Tushar Misra.
View institutional ownership trends
.

How do I buy shares of Mersana Therapeutics?

Shares of MRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mersana Therapeutics' stock price today?

One share of MRSN stock can currently be purchased for approximately $6.66.

How much money does Mersana Therapeutics make?

Mersana Therapeutics (NASDAQ:MRSN) has a market capitalization of $664.49 million and generates $40,000.00 in revenue each year. The company earns $-170,060,000.00 in net income (profit) each year or ($2.43) on an earnings per share basis.

How many employees does Mersana Therapeutics have?

The company employs 169 workers across the globe.

How can I contact Mersana Therapeutics?

Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The official website for the company is www.mersana.com. The company can be reached via phone at (617) 498-0020 or via email at ir@mersana.com.

This page (NASDAQ:MRSN) was last updated on 11/30/2022 by MarketBeat.com Staff